Increased urinary uronic acid excretion in experimentally-induced renal papillary necrosis in rats.
We have evaluated the potential of urinary uronic acid measurement as an early indicator in the development of renal papillary necrosis (RPN). Urinary uronic acid was quantified with a range of other urinary biochemical parameters in rats given multiple doses of N-phenylanthranilic acid (NPAA) or mefenamic acid (MFA), each of which induces a dose-related papillary necrosis. In addition, histological examination was also carried out to confirm the development and presence of RPN. NPAA was administered to male wistar rats at p.o. doses of 100, 250, and 500 mg/kg and MFA at p.o. doses of 75, 150, and 300 mg/kg on days 1-4 and 8-11, and urine samples were collected for 16 hours each day. NPAA increased uronic acid excretion two-fold for both medium and high doses from day four. MFA increased uronic acid excretion to two and a half-fold by day 10 in the highest dose administered. Urinary creatinine was equally elevated in a dose-related manner following treatment with either NPAA or MFA. None of the other routine markers (urinary or serum) of nephrotoxicity showed any statistical changes. NPAA produced a dose- and time-related increase in excretion of uronic acid. Evidence of widespread papillary necrosis was seen histologically at the high doses of NPAA or MFA. The significant elevation of uronic acid in urine following treatment with either NPAA or MFA was well ahead of the development of RPN detectable by routine histology, suggesting that uronic acid measurement could serve as an early indicator of RPN. The assessment of urinary uronic acid may therefore provide a novel sensitive and selective marker of identifying the lesion earlier than is currently possible. An increase in urinary uronic acid following NPAA and MFA treatment supports the biochemical basis of these changes as a representative of acid mucopolysaccharides accumulation.
Nguyen
T K
TK
Pharmaceutical Sciences Research Institute, Aston University, Birmingham, UK. t.k.t.nguyen@aston.ac.uk
Obatomi
D K
DK
Bach
P H
PH
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers / Q000652:urine; D003404:Creatinine / Q000652:urine; D007681:Kidney Papillary Necrosis / Q000139:chemically induced / Q000175:diagnosis / Q000652:urine*; D008297:Male; D008528:Mefenamic Acid; D051381:Rats; D017208:Rats, Wistar; D014574:Uronic Acids / Q000652:urine*; D062367:ortho-Aminobenzoates
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015415:Biomarkers; D014574:Uronic Acids; D062367:ortho-Aminobenzoates; D008528:Mefenamic Acid; C001209:fenamic acid; D003404:Creatinine